Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 26, 2003

View Archived Issues

Increased antitumor effects of bevacizumab plus 5-FU/leucovorin in colorectal cancer

Onercept effective and well tolerated in Crohn's disease

Kowa claims four series of cell adhesion inhibitors for allergy, asthma, etc.

New 5-HT receptor modulators and their use claimed in Pharmacia patent

Neurogen identifies compounds with affinity for GABA-A receptors

New GSK-3 inhibitors in AstraZeneca development pipeline

Chemokine CCR4 receptor modulators designed by Tularik researchers

Orion scientists prepare inhibitors of Na+/Ca2+ exchange with potential as antiarrhythmic agents

Gentris and Sankyo establish pharmacogenomics partnership

Enrollment completed in phase III PRIMO-CABG trial of pexelizumab

Medinox completes phase I study for MX-1094 for arthritis

CPMP recommends approval of Remicade for ankylosing spondylitis, label expansion

Positive opinion for Aldurazyme in E.U.

Viread recommended for approval in E.U. for use in treatment-naive HIV patients

Resiquimod development suspended following disappointing preliminary trial data

GlaxoSmithKline develops new meningitis vaccine for Africa

TaiGen and Fujisawa sign licensing and collaboration agreement

Aventis and CSL discuss potential acquisition of Aventis Behring

Fujisawa seeks European marketing clearance for candin antifungal agent

Targeting scavenger receptor BI for the treatment of infection, sepsis and inflammation

Licensing opportunity: murine MAb for detecting and quantitating CXCR4

Initial phase III AIDSVAX results do not reach primary endpoint

Retisert filing for posterior uveitis now scheduled for mid-2004

Dual inhibitor of Src and Abl kinases SKI-606 exerts potent antileukemic activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...